Sacituzumab-based CAR-T (Dana-Farber Cancer Institute)

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug NameSacituzumab-based CAR-T (Dana-Farber Cancer Institute)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Trop-2

TargetsTumor-associated calcium signal transducer 2

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesDana-Farber Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer Institute

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A